



June Quarterly Shareholder Update

Gary Phillips, CEO



FORWARD LOOKING STATEMENT

This document contains forward-looking statements, including statements concerning Syntara's future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Syntara as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown

risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

June Quarter 2026 - Highlights

- **Positive US FDA feedback supports the proposed clinical development pathway via Phase 2b trial of amsulostat in myelofibrosis**
- **\$8.0 million institutional placement strengthens balance sheet and extends expected cash runway into FY28**
- **Subsequent to the end of the quarter:**
 - **Preliminary Phase 2 SNT-4728 results show a statistically significant reduction in inflammation within a key Parkinson's disease-related brain region**
 - **SNT-9465 Phase 1b hypertrophic scar trial reaches 60% treatment commencement, with recruitment completion targeted for Q3 2026**
 - **AZALOX MDS study advances to final Phase 1b dose cohort**
- **Multiple clinical catalysts expected in H2 2026, including complete SNT-4728 data, amsulostat MDS interim results and SNT-9465 top-line results**

SHAREHOLDERS & CASH

Financial Information (ASX: SNT)

Share price – 23 July 2026	\$0.024
Market cap	A\$47m
Cash balance (30 Jun 2026)	A\$13.5m
Enterprise value	A\$33.5m

Institutional Ownership 30 Jun 26

D&A Income Limited	18%
Platinum Investment Management Limited	12%

Total Institutional Ownership > 44%

Research Coverage

Canaccord Genuity	Euroz Hartleys
Bell Potter	Evolution Capital

Share Price & Volume - YTD



* 11 August 2025 recorded volume was 119,820,710 following announcement of FDA guidance for amsulostat

THREE ASSETS CREATE MULTIPLE PATHS TO VALUE

A diversified clinical-stage pipeline across blood cancers, fibrosis and neurodegenerative disease

ASSET	INDICATION	TOTAL ADDRESSABLE MARKET	DEVELOPMENT STATUS
 amsulostat	Haematological malignancies	Myelofibrosis: ~US\$2.8b p.a. Myelodysplastic syndrome: ~US\$3.2b p.a.	• Phase 2a clinical proof of concept in MF - complete • FDA-aligned planned Phase 2b pathway – Q4 26 start • AZALOX and MESSAGE MDS studies – preliminary data Q4 26
 SNT-9465	Fibrosis and skin scarring	Global scar-treatment market projected to reach US\$50–55b by 2030.	• Hypertrophic-scar Phase 1b program – recruiting • Top-line safety and efficacy data targeted in H2 2026.
 SNT-4728	Parkinson's disease and iRBD	Global Parkinson's disease market expected to reach US\$7.6b by 2030.	• Phase 2 iRBD/Parkinson's program – preliminary data reported • Final study results in Q3 2026.

SUMMARY AND NEXT STEPS

Top-line Phase 2a data highlights amsulostat's potential in MF

Improvements of 50% or more in total symptom score (TSS50)

were observed quickly (as early as 12 weeks) and were sustained, with 73% (8/11) of patients achieving TSS50 at Week 24 or beyond

Meaningful spleen volume reductions (SVR) were observed

at 24 weeks and maintained thereafter, with 44% (4/9) of patients achieving SVR25 at Week 24 or beyond

Of the 7 patients that completed 52 weeks of treatment

- 6 chose to continue on amsulostat through named patient supply
- 3 of these patients had a minor anaemia response
- 2 achieved a complete (100%) resolution of symptoms from baseline

Differentiated TPP

- Competitive safety and efficacy profile in suboptimal MF JAKi patients
- Potential for disease modification and use in earlier stage MF
- Positive FDA review of Phase 2b trial protocol clears next stage of clinical development

Next phase of development and study design for BRIDGE-MF guided by clinical advisory board and aligned with recent FDA feedback.

STRONG INTEREST IN MF ASSETS FROM STRATEGICS

Target / Acquiror



DATE OF
ANNOUNCEMENT*

JULY-2026

APRIL-2026

MARCH-2026

DEC-2024

FEB-2024

Drug Name

Navtemadlin

AJ1-11095

Rovadicitinib

Elritercept

Pelabresib

Lead Indication /
Phase (at transaction)

Myelofibrosis
(ongoing Phase 3)

Myelofibrosis
(ongoing Phase 1)

Myelofibrosis
(completed Phase 2)

MDS and MF
(ongoing Phase 2
trials)

Myelofibrosis
(successful Phase 3
studies)

Deal Type

Acquisition

Acquisition

License

License

Acquisition

Upfront /
Milestones (US\$)

US\$450M /
US\$1.3B

Total deal value
US\$2.3B

US\$135M /
US\$1.395B

US\$200M /
US\$1.1B

US\$2.9B

Earnout Payments /
Royalty Rate (%)

Not disclosed

Not disclosed

Not disclosed

Not disclosed

Subject to regulatory
approvals

Attractive commercial outcomes for drugs with Phase 2 and 3 data
expected to drive interest in amsulostat Phase 2 data

AMSULOSTAT: A NEW FUTURE IN MF TREATMENT OPTIONS

Aspirational lifecycle development in MF enabled by first in class pan-LOX mechanism

Ideal add-on for patients with sub-optimal response to JAKi

- FDA endorsed phase 2b protocol
- Pan-lysyl oxidase inhibition mechanism and favourable tolerability support combination use with JAKi.
- Inhibition of LOX-mediated PDGFR signalling enhances impact of JAKi on cell proliferation.
- Potential to improve symptoms and extend the useful treatment duration of JAKi through effects on the bone marrow microenvironment

Market
Opportunity
~\$1b

Potentially best positioned in frontline combination with JAKi

- Pan-lysyl oxidase inhibition mechanism and favourable tolerability profile makes amsulostat well suited for early combination use.
- Targeting fibrosis biology and microenvironmental signaling complements JAK inhibition.
- Early use maximises impact on symptoms, spleen response and longer-term disease biology.

Market
Opportunity
~\$1.8b

Opportunity to slow progression in newly diagnosed MF

- Pan-lysyl oxidase inhibition may preserve and restore the bone microenvironment to slow disease progression.
- Strong tolerability supports use earlier in treatment paradigm, before patients become symptomatic.
- Potential for disease modification and improved survival is maximised when used early.


Market
Opportunity
~\$2.8b

REDUCTION IN INFLAMMATION


Statistically significant reduction in brain inflammation observed unilaterally in the putamen (p-value 0.0145)

- The putamen is a key region underlying the hallmark motor symptoms of Parkinson’s disease.
- 20 out of 30 pts on active treatment (SNT-4728) recorded a reduction in inflammation from baseline.
- No statistically significant change in inflammation was detected in other predefined regions of interest.
- No significant reduction in brain inflammation in any region for placebo group.

Putamen	Binding Potential (BP _{ND})		Mean change	P-value (Paired t-test)
	Mean at baseline	Mean at 12 weeks		
Right	0.002918	-0.012073	-0.016 (0.033)	0.0145
Left	-0.001209	0.001692	0.003 (0.029)	0.6219



20/30 pts had reduced inflammation after 12 weeks treatment.



At week 12, inflammation significantly reduced compared to placebo.

BP_{ND} is a dimensionless number expressing the distribution volume ratio of specifically bound radioligand to that of non-displaceable radioligand.

INNOVATIVE TRIAL DESIGN TO EVALUATE COMMERCIAL VIABILITY

Placebo controlled scar remodeling study with multiple efficacy readouts in H2 2026


Healthy Volunteer Phase 1a Single Ascending Dose

- ✓ Dose-dependent target engagement confirmed



Hypertrophic scars Phase 1b Multiple Daily Dose

Randomized, Double-blinded,
Placebo-controlled Split-scar Study in Adult Participants with
Hypertrophic Sternotomy Scars (N=20)



Trial design optimised for inclusion criteria and endpoints





PRIMARY ENDPOINT

- Safety TEAEs

SECONDARY ENDPOINTS

- Pharmacokinetics / Pharmacodynamics
- Scar rating (multiple blinded raters)
- 3D imaging (scar volume)
- Optical Coherence Tomography (OCT)
- Elastography
- Patient and Observer Scar Assessment Scale (POSAS)

THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE

TARGET	DRUG	INDICATION	PARTNERS	PHASE 1		PHASE 2	ANTICIPATED NEWS FLOW		
				HEALTHY PARTICIPANTS	PATIENTS		H1 2026	H2 2026	
Pan-LOX	Amsulostat (SNT-5505)	Myelofibrosis					FDA approved development plan and partner engagement	Trial Progression	
		High Risk MDS AZALOX trial						Interim safety and efficacy data Phase 2 initiation	
		Low / Int Risk MDS MESSAGE trial						Interim safety and efficacy data	
		Pancreatic cancer FALCON trial						Investigator Study TBD	
Topical Pan-LOX	SNT-9465	Hypertrophic scarring					Recruit hypertrophic scar Phase 1b trial	Top Line safety and efficacy data	
	SNT-6302	Keloid scarring						Interim safety and efficacy data	
Dual SSAO & MAO-B	SNT-4728	IRBD / Parkinson's Disease	In partnership with 					Phase 2 Top Line data	Phase 2 full results

<http://syntaratx.com.au>



Gary Phillips
Chief Executive Officer
gary.phillips@syntaratx.com.au

Alison Findlay
Head Business Development & Licensing
alison.findlay@syntaratx.com.au